SCHEMBL24369751

SCHEMBL24369751

COC(=O)c1ncc(Br)cc1CN(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 10/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 3/20 0.36
POLB P06746 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GMNN O75496 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
GABRA1 P14867 1/20 0.36
TSHR P16473 1/20 0.36
GABRG2 P18507 1/20 0.36
NFKB1 P19838 1/20 0.36
APEX1 P27695 1/20 0.36
GABRB3 P28472 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289465 0.83 CYP4F2 (0.40) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL30745103 0.83 CYP4F2 (0.40) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL30744962 0.82 OPRK1 (0.38) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL20944537 0.82 OPRK1 (0.38) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL22117014 0.78 TSHR (0.36) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL25171205 0.78 OPRK1 (0.36) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL31027123 0.78 OPRK1 (0.36) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL6057160 0.76 NPSR1 (0.43) OPRK1KMT2ATSHRMAPK1NPSR1
SCHEMBL14875875 0.75 CYP1A2 (0.36) OPRK1ALDH1A1POLBKDM4EGMNN
SCHEMBL21591066 0.74 NPSR1 (0.42) OPRK1ALDH1A1POLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331046-B2 CTPS1 inhibitors and uses thereof NIMBUS CLOTHO, INC. (US) 2025-06-17 US disclosed
EP-4232425-A1 CTPS1 INHIBITORS AND USES THEREOF Nimbus Clotho, Inc. (US) 2023-08-30 EP disclosed
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-09 US disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF CTPS1, CTPS2, ECHS1 OPRK1 4513/4885MEN1 4328/4885KMT2A 3259/4885
US-12331046-B2 CTPS1 inhibitors and uses thereof CTPS1, CTPS2, ECHS1 OPRK1 4513/4885MEN1 4328/4885KMT2A 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.